Table 2.

Total cholesterol and LDL cholesterol at Baseline and 12 mo and change from Baseline to 12 mo (12‐mo population) in patients with baseline levels below or above the upper limit of the reference range

Treatment	n	Baseline, mean (SD)		12‐mo treatment a , mean (SD)	Analysis of covariance model b Change in lipid levels from Baseline at 12 mo
					n	LS mean (SE)	P‐value (treatment)
Total cholesterol below upper limit of the reference range at Baseline c
LCM, mg/dL	87	170.2 (23.3)		173.6 (32.2)	86	3.0 (2.6)	<.001
CBZ, mg/dL	92	162.6 (28.2)		185.60 (32.8)***	92	23.5 (2.6)
Total cholesterol above upper limit of the reference range at Baseline d
LCM, mg/dL	51	225.6 (21.5)		214.9 (30.6)**	51	−9.3 (3.5)	<.001
CBZ, mg/dL	41	228.0 (20.2)		243.7 (29.3)***	41	15.9 (3.9)
LDL cholesterol below upper limit of the reference range at Baseline e
LCM, mg/dL	102	97.6 (20.8)		98.4 (26.7)	101	0.8 (2.0)	<.001
CBZ, mg/dL	105	90.2 (23.1)		103.7 (27.8)***	105	13.5 (2.0)
LDL cholesterol above upper limit of the reference range at Baseline f
LCM, mg/dL	36	146.4 (15.0)	137.5 (24.3)*		36	−8.3 (3.9)	.003
CBZ, mg/dL	26	151.9 (13.9)	161.1 (23.1)		26	10.5 (4.6)

Abbreviations: ANCOVA, analysis of covariance; CBZ, carbamazepine; LCM, lacosamide; LDL, low‐density lipoprotein; LS, least squares; SD, standard deviation; SE, standard error.

^aThe 12‐mo lipid levels included lipid values collected at 364 d (plus a 30‐d window) of treatment during the Treatment period.

^bThe ANCOVA model included treatment as a main effect and age, sex, body mass index, and Baseline lipid level as covariates.

^cTotal cholesterol levels ≤200 mg/dL.

^dTotal cholesterol levels >200 mg/dL.

^eLDL‐cholesterol levels ≤130 mg/dL.

^fLDL‐cholesterol levels >130 mg/dL. Within treatment group comparison 12‐mo vs Baseline; paired t test.

^* P < .05.

^** P < .01.

^*** P < .001.